{
    "id": "45690249",
    "text": "3D molecular rendering of methylphenidate (MPH) This is a list of methylphenidate (MPH or MPD) analogues, or Phenidates. The most well known compound from this family, methylphenidate, is widely prescribed around the world for the treatment of attention deficit hyperactivity disorder (ADHD) and certain other indications. Several other derivatives including rimiterol, phacetoperane and pipradrol also have more limited medical application. A rather larger number of these compounds have been sold in recent years as designer drugs, either as quasi-legal substitutes for illicit stimulants such as methamphetamine or cocaine, or as purported \"study drugs\" or nootropics.Klare H, Neud\u00f6rfl JM, Brandt SD, Mischler E, Meier-Giebing S, Deluweit K, Westphal F, Laussmann T. Analysis of six 'neuro-enhancing' phenidate analogs. Drug Test Anal. 2017 Mar;9(3):423-435. Luethi D, Kaeser PJ, Brandt SD, Kr\u00e4henb\u00fchl S, Hoener MC, Liechti ME. Pharmacological profile of methylphenidate-based designer drugs. Neuropharmacology. 2018 May 15;134(Pt A):133-140. Carlier J, Giorgetti R, Var\u00ec MR, Pirani F, Ricci G, Busard\u00f2 FP. Use of cognitive enhancers: methylphenidate and analogs. Eur Rev Med Pharmacol Sci. 2019 Jan;23(1):3-15. More structurally diverse compounds such as Desoxypipradrol (and thus Pipradrol, including such derivatives as AL-1095, Diphemethoxidine, SCH-5472 and D2PM), and even mefloquine, 2-benzylpiperidine, rimiterol, enpiroline and DMBMPP, can also be considered structurally related, with the former ones also functionally so, as loosely analogous compounds. The acyl group has sometimes been replaced with similar length ketones to increase duration. Alternatively, the methoxycarbonyl has in some cases been replaced with an alkyl group. Dozens more phenidates and related compounds are known from the academic and patent literature, and molecular modelling and receptor binding studies have established that the aryl and acyl substituents in the phenidate series are functionally identical to the aryl and acyl groups in the phenyltropane series of drugs, suggesting that the central core of these molecules is primarily acting merely as a scaffold to correctly orientate the binding groups, and for each of the hundreds of phenyltropanes that are known, there may be a phenidate equivalent with a comparable activity profile. ==Notable phenidate derivatives== General structure of phenidate derivatives, where R is nearly always hydrogen but can be alkyl, R1 is usually phenyl or substituted phenyl but rarely other aryl groups, R2 is usually acyl but can be alkyl or other substitutions, and Cyc is nearly always piperidine but rarely other heterocycles {| class=\"wikitable\" style=\"background: #FFFFFF\" |- ! Structure ! Common name ! Chemical name ! CAS number ! R1 ! R2 |- | 115px | 2-BZPD | 2-Benzylpiperidine | 32838-55-4 | phenyl | H |- | 115px | Ritalinic acid | Phenyl(piperidin-2-yl)acetic acid | 19395-41-6 | phenyl | COOH |- | 115px | Ritalinamide | 2-Phenyl-2-(piperidin-2-yl)acetamide | 19395-39-2 | phenyl | CONH2 |- | 115px | Methylphenidate (MPH) | Methyl phenyl(piperidin-2-yl)acetate | 113-45-1 | phenyl | COOMe |- | 115px | Phacetoperane (Lid\u00e9pran) | [(R)-phenyl-[(2R)-piperidin-2-yl]methyl] acetate | 24558-01-8 | phenyl | OCOMe |- | 120px | Rimiterol | 4-{(S)-hydroxy[(2R)-piperidin-2-yl]methyl}benzene-1,2-diol | 32953-89-2 | 3,4-dihydroxyphenyl | hydroxy |- | 115px | Ethylphenidate (EPH) | Ethyl phenyl(piperidin-2-yl)acetate | 57413-43-1 | phenyl | COOEt |- | 115px | Propylphenidate (PPH) | Propyl phenyl(piperidin-2-yl)acetate | 1071564-47-0 | phenyl | COOnPr |- | 115px | Isopropylphenidate (IPH) | Propan-2-yl 2-phenyl-2-(piperidin-2-yl)acetate | 93148-46-0 | phenyl | COOiPr |- | 115px | Butylphenidate (BPH) | Butyl phenyl(piperidin-2-yl)acetate | | phenyl | COOnBu |- | 115px | 3-Chloromethylphenidate (3-Cl-MPH) | Methyl 2-(3-chlorophenyl)-2-(piperidin-2-yl)acetate | 191790-73-5 | 3-chlorophenyl | COOMe |- | 115px | 3-Bromomethylphenidate (3-Br-MPH) | Methyl 2-(3-bromophenyl)-2-(piperidin-2-yl)acetate | | 3-bromophenyl | COOMe |- | 115px | 4-Fluoromethylphenidate (4F-MPH) | Methyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate | 1354631-33-6 | 4-fluorophenyl | COOMe |- | 115px | 4-Fluoroethylphenidate (4F-EPH) | Ethyl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate | 2160555-59-7 | 4-fluorophenyl | COOEt |- | 115px | 4-Fluoroisopropylphenidate (4F-IPH) | Propan-2-yl 2-(4-fluorophenyl)-2-(piperidin-2-yl)acetate | | 4-fluorophenyl | COOiPr |- | 115px | 4-Chloromethylphenidate (4-Cl-MPH) | Methyl 2-(4-chlorophenyl)-2-(piperidin-2-yl)acetate | 680996-44-5 | 4-chlorophenyl | COOMe |- | 115px | 3,4-Dichloromethylphenidate (3,4-DCMP) | Methyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate | 1400742-68-8 | 3,4-dichlorophenyl | COOMe |- | 115px | 3,4-Dichloroethylphenidate (3,4-DCEP) | Ethyl 2-(3,4-dichlorophenyl)-2-(piperidin-2-yl)acetate | | 3,4-dichlorophenyl | COOEt |- | 115px | 4-Bromomethylphenidate (4-Br-MPH) | Methyl 2-(4-bromophenyl)-2-(piperidin-2-yl)acetate | 203056-13-7 | 4-bromophenyl | COOMe |- | 115px | 4-Bromoethylphenidate (4-Br-EPH) | Ethyl 2-(4-bromophenyl)-2-(piperidin-2-yl)acetate | 1391486-43-3 | 4-bromophenyl | COOEt |- | 115px | 4-Methylmethylphenidate (4-Me-MPH) | Methyl 2-(4-methylphenyl)-2-(piperidin-2-yl)acetate | 191790-79-1 | 4-methylphenyl | COOMe |- | 120px | 4-Nitromethylphenidate (4-NO2-MPH) | Methyl 2-(4-nitrophenyl)-2-(piperidin-2-yl)acetate | | 4-nitrophenyl | COOMe |- | 120px | Methylenedioxymethylphenidate (MDMPH) | Methyl (1,3-benzodioxol-5-yl)(piperidin-2-yl)acetate | | 3,4-methylenedioxyphenyl | COOMe |- | 120px | Methylnaphthidate (HDMP-28) | Methyl (naphthalen-2-yl)(piperidin-2-yl)acetate | 231299-82-4 | naphthalen-2-yl | COOMe |- | 120px | Ethylnaphthidate (HDEP-28) | Ethyl (naphthalen-2-yl)(piperidin-2-yl)acetate | | naphthalen-2-yl | COOEt |- | 115px | MTMP | Methyl (thiophen-2-yl)(piperidin-2-yl)acetate | | thiophen-2-yl | COOMe |- | 115px | \u03b1-acetyl-2-benzylpiperidine | 1-Phenyl-1-(piperidin-2-yl)propan-2-one | | phenyl | acetyl |- | 115px | CPMBP | 2-[1-(3-chlorophenyl)-3-methylbutyl]piperidine | | 3-chlorophenyl | isobutyl |- | 115px | Desoxypipradrol (2-DPMP) | 2-benzhydrylpiperidine | 519-74-4 | phenyl | phenyl |- | 115px | Pipradrol (Meratran) | Diphenyl(piperidin-2-yl)methanol | 467-60-7 | phenyl | hydroxy,phenyl |} ;Related compounds A number of related compounds are known which fit the same general structural pattern, but with substitution on the piperidine ring (e.g. SCH-5472, Difemetorex, N-benzylethylphenidate), or the piperidine ring replaced by other heterocycles such as pyrrolidine (e.g. diphenylprolinol, 2-Diphenylmethylpyrrolidine), morpholine (e.g. Methylmorphenate, 3-Benzhydrylmorpholine) or quinoline (e.g. AL-1095, Butyltolylquinuclidine). {| class=\"wikitable\" style=\"background: #FFFFFF\" |- ! Structure ! Common name ! Chemical name ! CAS number |- | 115px | SCH-5472 | 2-benzhydryl-1-methyl- piperidin-3-ol | 20068-90-0 |- | 115px | Difemetorex | 2-[2-(diphenylmethyl)piperidin-1-yl]ethanol | 13862-07-2 |- | 115px | N-benzylethylphenidate | Ethyl (1-benzylpiperidin-2-yl)(phenyl)acetate | |- | 130px | DMBMPP | 2-(2,5-dimethoxy-4-bromobenzyl)-6-(2-methoxyphenyl)piperidine | 1391499-52-7 |- | 115px | Diphenylprolinol (D2PM) | diphenyl(pyrrolidin-2-yl)methanol | 22348-32-9 |- | 115px | 2-Benzhydrylpyrrolidine | 2-(Diphenylmethyl)pyrrolidine | 119237-64-8 |- | 115px | HDMP-29 | Methyl (naphthalen-2-yl)(pyrrolidin-2-yl)acetate | |- | 115px | Methylmorphenate | Methyl morpholin-3-yl(phenyl)acetate | |- | 115px | 3-Benzhydrylmorpholine | 3-(diphenylmethyl)morpholine | 93406-27-0 |- | 120px | AL-1095 | 2-(1-phenyl-1-(p-chlorophenyl)methyl)-3-hydroxyquinuclidine | 54549-19-8 |- | 115px | Butyltolylquinuclidine | (2R,3S,4S)-2-butyl-3-p-tolylquinuclidine | |} ==Isomerism== 'flexed' or \"chair\" conformation. (the latter term can denote a structure containing a bridge in the ring when so-named, unlike the above). N.B. although the cyclohexane conformation, if considering both the hydrogen on the plain bond and the implicit carbon on the dotted bond are not shown as positioned as would be for the least energy state inherent to what rules apply, internally, to the molecule in and of itself: possibility of movement between putative other ligand sites in suchwise, here regarding what circumstance allows for describing it as \"flexed\" thus mean it has shown tendency for change in situ depending on its environment and adjacent sites of potential interaction as against its least energy state. Methylphenidate (and its derivatives) have two chiral centers, meaning that it, and each of its analogues, have four possible enantiomers, each with differing pharmacokinetics and receptor binding profiles. In practice methylphenidate is most commonly used as pairs of diastereomers rather than isolated single enantiomers or a mixture of all four isomers. Forms include the racemate, the enantiopure (dextro or levo) of its stereoisomers; erythro or threo (either + or -) among its diastereoisomers, the chiral isomers S,S; S,R/R,S or R,R and, lastly, the isomeric conformers (which are not absolute) of either its anti- or gauche- rotamer. The variant with optimized efficacy is not the usually attested generic or common pharmaceutical brands (e.g. Ritalin, Daytrana etc.) but the (R,R)-dextro-(+)-threo-anti (sold as Focalin), which has a binding profile on par with or better than that of cocaine. (Note however the measure of fivefold (5\u00d7) discrepancy in the entropy of binding at their presumed shared target binding site, which may account for the higher abuse potential of cocaine over methylphenidate despite affinity for associating; i.e the latter dissociates more readily once bound despite efficacy for binding.) Furthermore, the energy to change between its two rotamers involves the stabilizing of the hydrogen bond between the protonated amine (of an 8.5 pKa) with the ester carbonyl resulting in reduced instances of \"gauche\u2014gauche\" interactions via its favoring for activity the \"anti\"-conformer for putative homergic-psychostimulating pharmacokinetic properties, postulating that one inherent conformational isomer (\"anti\") is necessitated for the activity of the threo diastereoisomer. Also of note is that methylphenidate in demethylated form is acidic; a metabolite (and precursor) known as ritalinic acid. This gives the potential to yield a conjugate salt form effectively protonated by a salt nearly chemically duplicate/identical to its own structure; creating a \"methylphenidate ritalinate\". ==Receptor binding profiles of selected methylphenidate analogues== ===Aryl substitutions=== {| class=\"wikitable sortable\" |+Phenyl ring substituted methylphenidate analogues ! Compound ! S. Singh's alphanumeric assignation (name) ! R1 ! R2 ! IC50 (nM) (Inhibition of [3H]WIN 35428 binding) ! IC50 (nM) (Inhibition of [3H]DA uptake) ! Selectivity uptake/binding |- |rowspan=5|x140px |- | (D-threo-methylphenidate) ||rowspan=4, colspan=2| H, H || 33 ||244 \u00b1 142 (171 \u00b1 10)||7.4 |- | (L-threo-methylphenidate) || 540 || 5100 (1468 \u00b1 112)||9.4 |- | (D/L-threo-methylphenidate) \"eudismic ratio\" || 6.4 || 20.9 (8.6) || - |- | (DL-threo-methylphenidate) ||83.0 \u00b1 7.9||224 \u00b1 19||2.7 |- | x140px || (R-benzoyl-methylecgonine) (cocaine) ||colspan=2| (H, H) ||173 \u00b1 13||404 \u00b1 26||2.3 |- |rowspan=17|x140px |- | 351a (4F-MPH) || F ||rowspan=29|H y d r o g e n i.e. H ||35.0 \u00b1 3.0||142 \u00b1 2.0||4.1 |- | 351b || Cl ||20.6 \u00b1 3.4||73.8 \u00b1 8.1||3.6 |- | 351c || Br ||6.9 \u00b1 0.1||26.3 \u00b1 5.8||3.8 |- | 351d || (d) Br || - ||22.5 \u00b1 2.1|| - |- | 351e || (l) Br || - ||408 \u00b1 17|| - |- | 351d/e \"eudismic ratio\" || (d/l) Br || - || 18.1 || - |- | 351f || I ||14.0 \u00b1 0.1||64.5 \u00b1 3.5||4.6 |- | 351g || OH ||98.0 \u00b1 10||340 \u00b1 70||3.5 |- | 351h || OCH3 ||83 \u00b1 11||293 \u00b1 48||3.5 |- | 351i || (d) OCH3 || - ||205 \u00b1 10|| - |- | 351j || (l) OCH3 || - ||3588 \u00b1 310|| - |- | 351i/j \"eudismic ratio\" || (d/l) OCH3 || - || 17.5 || - |- | 351k (4-Me-MPH) || CH3 ||33.0 \u00b1 1.2||126 \u00b1 1||3.8 |- | 351l || t-Bu ||13500 \u00b1 450||9350 \u00b1 950||0.7 |- | 351m || NH2.HCl ||34.6 \u00b1 4.0||115 \u00b1 10||3.3 |- | 351n || NO2 ||494 \u00b1 33||1610 \u00b1 210||3.3 |- |rowspan=8|x140px |- | 352a || F ||40.5 \u00b1 4.5||160 \u00b1 0.00||4.0 |- | 352b || Cl ||5.1 \u00b1 1.6||23.0 \u00b1 3.0||4.5 |- | 352c || Br ||4.2 \u00b1 0.2||12.8 \u00b1 0.20||3.1 |- | 352d || OH ||321 \u00b1 1.0||790 \u00b1 30||2.5 |- | 352e || OMe ||288 \u00b1 53||635 \u00b1 35||0.2 |- | 352f || Me ||21.4 \u00b1 1.1||100 \u00b1 18||4.7 |- | 352g || NH2.HCl ||265 \u00b1 5||578 \u00b1 160||2.2 |- |rowspan=5|x140px|| 353a || 2\u2032-F ||1420 \u00b1 120||2900 \u00b1 300||2.1 |- | 353b || 2\u2032-Cl ||1950 \u00b1 230||2660 \u00b1 140||1.4 |- | 353c || 2\u2032-Br ||1870 \u00b1 135||3410 \u00b1 290||1.8 |- | 353d || 2\u2032-OH ||23100 \u00b1 50||35,800 \u00b1 800||1.6 |- | 353e || 2\u2032-OCH3 ||101,000 \u00b1 10,000||81,000 \u00b1 2000||0.8 |- |rowspan=3|x140px|| 354a (3,4-DCMP) ||colspan=2| Cl, Cl (3\u2032,4\u2032-Cl2)||5.3 \u00b1 0.7||7.0 \u00b1 0.6||1.3 |- | 354b || I || OH ||42 \u00b1 21||195 \u00b1 197||4.6 |- | 354c ||colspan=2| OMe, OMe (3\u2032,4\u2032-OMe2)||810 \u00b1 10||1760 \u00b1 160||2.2 |} Both analogues 374 & 375 displayed higher potency than methylphenidate at DAT. In further comparison, 375 (the 2-naphthyl) was additionally two & a half times more potent than 374 (the 1-naphthyl isomer). ===Aryl exchanged analogues=== {| class=\"wikitable sortable\" |+Phenyl ring modified methylphenidate analogues ! Compound ! S. Singh's alphanumeric assignation (name) ! Ring ! Ki (nM) (Inhibition of [125I]IPT binding) ! Ki (nM) (Inhibition of [3H]DA uptake) ! Selectivity uptake/binding |- | x110px || (D-threo-methylphenidate) ||rowspan=2|benzene || 324 || - || - |- | x150px || (DL-threo-methylphenidate) ||82 \u00b1 77||429 \u00b1 88||0.7 |- | x150px || 374 || 1-naphthalene ||194 \u00b1 15||1981 \u00b1 443||10.2 |- | x150px || 375 (HDMP-28) || 2-naphthalene || 79.5 ||85.2 \u00b1 25||1.0 |- | x180px || 376 || benzyl || >5000 || - || - |} HDMP-29, a manifold (multiple augmented) analogue of both the phenyl (to a 2-naphthalene) and piperidine (to a 2-pyrrolidine) rings. ===Piperidine nitrogen methylated phenyl-substituted variants=== {| class=\"wikitable sortable\" |+N-methyl phenyl ring substituted methylphenidate analogues ! Compound ! S. Singh's alphanumeric assignation (name) ! R ! IC50 (nM) (Inhibition of binding at DAT) |- |rowspan=6|x150px |- | 373a || H ||500 \u00b1 25 |- | 373b || 4\u2033-OH ||1220 \u00b1 140 |- | 373c || 4\u2033-CH3 ||139 \u00b1 13 |- | 373d || 3\u2033-Cl ||161 \u00b1 18 |- | 373e || 3\u2033-Me ||108 \u00b1 16 |} HDEP-28, Ethylnaphthidate. ===Cycloalkane extensions, contractions & modified derivatives=== {| class=\"wikitable sortable\" |+Piperidine ring modified methylphenidate analogues ! Compound ! S. Singh's alphanumeric assignation (name) ! Cycloalkane ring ! Ki (nM) (Inhibition of binding) |- | x150px || 380 || 2-pyrrolidine (cyclopentane) ||1336 \u00b1 108 |- | x150px || 381 || 2-azepane (cycloheptane) ||1765 \u00b1 113 |- | x150px || 382 || 2-azocane (cyclooctane) ||3321 \u00b1 551 |- | x150px || 383 || 4-1,3-oxazinane (cyclohexane) ||6689 \u00b1 1348 |} {| class=\"wikitable\" align=\"right\" width=50 |- |x170px Methyl 2-(1,2-oxazinan-3-yl)-2-phenylacetate |- |x170px Methyl 2-(1,3-oxazinan-2-yl)-2-phenylacetate |- |\u261dThe two other (in addition to compound 383) potential oxazinane methylphenidate analogues. |} {| class=\"wikitable\" align=\"right\" width=50 |- |x170px Methyl 2-phenyl-2-(morpholin-3-yl)acetate A.K.A. Methyl 2-morpholin-3-yl-2-phenylacetate||\u261cMethylmorphenate methylphenidate analogue. |} ===Azido-iodo-N-benzyl analogues=== Structures of Azido-iodo-N-benzyl analogues of methylphenidate with affinities. {| class=\"wikitable sortable\" |+Azido-iodo-N-benzyl methylphenidate analogs inhibitition of [3H]WIN 35428 binding and [3H]dopamine uptake at hDAT N2A neuroblastoma cells. (Each Ki or IC50 value represents data from at least three independent experiments with each data point on the curve performed in duplicate) ! Structure ! Compound ! R1 ! R2 ! Ki (nM) (Inhibition of [3H]WIN 35428 binding) ! IC50 (nM) (Inhibition of [3H]DA uptake) |- | ||(\u00b1)\u2014threo-methylphenidate||H||H||25 \u00b1 1||156 \u00b1 58 |- | ||(\u00b1)\u20144-I-methylphenidate||para-iodo||H||14 \u00b1 3\u0251||11 \u00b1 2b |- | ||(\u00b1)\u20143-I-methylphenidate||meta-iodo||H||4.5 \u00b1 1\u0251||14 \u00b1 5b |- |rowspan=14|300px |- | (\u00b1)\u2014p-N3-N-Bn-4-I-methylphenidate||para- iodo||para-N3-N-Benzyl||363 \u00b1 28\u0251||2764 \u00b1 196bc |- | (\u00b1)\u2014m-N3-N-Bn-4-I-methylphenidate||para-iodo||meta-N3-N-Benzyl||2754 \u00b1 169\u0251||7966 \u00b1 348bc |- | (\u00b1)\u2014o-N3-N-Bn-4-I-methylphenidate||para- iodo||ortho-N3-N-Benzyl||517 \u00b1 65\u0251||1232 \u00b1 70bc |- | (\u00b1)\u2014p-N3-N-Bn-3-I-methylphenidate||meta-iodo||para-N3-N-Benzyl||658 \u00b1 70\u0251||1828 \u00b1 261bc |- | (\u00b1)\u2014m-N3-N-Bn-3-I-methylphenidate||meta- iodo||meta-N3-N-Benzyl||2056 \u00b1 73\u0251||4627 \u00b1 238bc |- | (\u00b1)\u2014o-N3-N-Bn-3-I-methylphenidate||meta-iodo||ortho-N3-N-Benzyl||1112 \u00b1 163\u0251||2696 \u00b1 178bc |- | (\u00b1)\u2014N-Bn-methylphenidate||H||N-Benzyl||\u2014||\u2014 |- | (\u00b1)\u2014N-Bn-3-chloro-methylphenidate||3-Cl||N-Benzyl||\u2014||\u2014 |- | (\u00b1)\u2014N-Bn-3,4-dichloro-methylphenidate||3,4-diCl||N-Benzyl||\u2014||\u2014 |- | (\u00b1)\u2014p-chloro-N-Bn-methylphenidate||H||para-Cl-N-Benzyl||\u2014||\u2014 |- | (\u00b1)\u2014p-methoxy-N-Bn-methylphenidate||H||para-OMe-N-Benzyl||\u2014||\u2014 |- | (\u00b1)\u2014m-chloro-N-Bn-methylphenidate||H||meta-Cl-N-Benzyl||\u2014||\u2014 |- | (\u00b1)\u2014p-nitro- N-Bn-methylphenidate||H||para-NO2-N-Benzyl||\u2014||\u2014 |} *\u0251p <0.05 versus Ki of (\u00b1)\u2014threo-methylphenidate. *bp <0.05 versus IC50 of (\u00b1)\u2014threo-methylphenidate. *cp <0.05 versus its corresponding Ki. ===Alkyl substituted-carbomethoxy analogues=== {| class=\"wikitable sortable\" |+Alkyl RR/SS diastereomer analogs of methylphenidate (RS/SR diastereomer values of otherwise same compounds given in small grey typeface) ! Structure ! R1 ! R2 ! R3 ! Dopamine transporter Ki (nM) (Inhibition of [I125H]RTI-55 binding) ! DA uptake IC50 (nM) ! Serotonin transporter Ki (nM) (Inhibition of [I125H]RTI-55 binding) ! 5HT uptake IC50 (nM) ! Norepinephrine transporter Ki (nM) (Inhibition of [I125H]RTI-55 binding) ! NE uptake IC50 (nM) !NE/DA selectivity (binding displacement) !NE/DA selectivity (uptake blocking) |- |Cocaine||\u2014 \u0251||\u2014 b||\u2014 c||500 \u00b1 65||240 \u00b1 15||340 \u00b1 40||250 \u00b1 40||500 \u00b1 90||210 \u00b1 30||1.0||0.88 |- |rowspan=29|300px |- |H||COOCH3||H||110 \u00b1 9||79 \u00b1 16||65,000 \u00b1 4,000||5,100 \u00b1 7,000||660 \u00b1 50||61 \u00b1 14||6.0||0.77 |- |4-chloro||COOCH3||H||25 \u00b1 8 2,000 \u00b1 600||11 \u00b1 28 2,700 \u00b1 1,000||6,000 \u00b1 100 5,900 \u00b1 200||>9,800 >10 mM||110 \u00b1 40 >6,100||11 \u00b1 3 1,400 \u00b1 400||4.4||1.0 |- |4-chloro||methyl||H||180 \u00b1 70 >3,900||22 \u00b1 7 1,500 \u00b1 700||4,900 \u00b1 500 >9,100||1,900 \u00b1 300 4,700 \u00b1 800||360 \u00b1 140 >6,300||35 \u00b1 13 3,200 \u00b1 800||2.0||1.6 |- |4-chloro||ethyl||H||37 \u00b1 10 1,800 \u00b1 300||23 \u00b1 5 2,800 \u00b1 700||7,800 \u00b1 800 4,200 \u00b1 400||2,400 \u00b1 400 4,100 \u00b1 1,000||360 \u00b1 60 >9,200||210 \u00b1 30 1,300 \u00b1 400||9.7||9.1 |- |4-chloro||propyl||H||11 \u00b1 3 380 \u00b1 40||7.4 \u00b1 0.4 450 \u00b1 60||2,700 \u00b1 600 3,200 \u00b1 1,100||2,900 \u00b1 1,100 1,300 \u00b1 7||200 \u00b1 80 1,400 \u00b1 400||50 \u00b1 15 200 \u00b1 50||18.0||6.8 |- |4-chloro||isopropyl||H||46 \u00b1 16 900 \u00b1 320||32 \u00b1 6 990 \u00b1 280||5,300 \u00b1 1,300 >10 mM||3,300 \u00b1 400 \u2014||810 \u00b1 170 >10 mM||51 \u00b1 20 \u2014||18.0||1.6 |- |4-chloro||butyl||H||7.8 \u00b1 1.1 290 \u00b1 70||8.2 \u00b1 2.1 170 \u00b1 40||4,300 \u00b1 400 4,800 \u00b1 700||4,000 \u00b1 400 3,300 \u00b1 600||230 \u00b1 30 1,600 \u00b1 300||26 \u00b1 7 180 \u00b1 60||29.0||3.2 |- |4-chloro||isobutyl||H||16 \u00b1 4 170 \u00b1 50||8.6 \u00b1 2.9 380 \u00b1 130||5,900 \u00b1 900 4,300 \u00b1 500||490 \u00b1 80 540 \u00b1 150||840 \u00b1 130 4,500 \u00b1 1,500||120 \u00b1 40 750 \u00b1 170||53.0||14.0 |- |4-chloro||pentyl||H||23 \u00b1 7 870 \u00b1 140||45 \u00b1 14 650 \u00b1 20||2,200 \u00b1 100 3,600 \u00b1 1,000||1,500 \u00b1 300 1,700 \u00b1 700||160 \u00b1 40 1,500 \u00b1 300||49 \u00b1 16 860 \u00b1 330||7.0||1.1 |- |4-chloro||isopentyl||H||3.6 \u00b1 1.2 510 \u00b1 170||14 \u00b1 2 680 \u00b1 120||5,000 \u00b1 470 6,700 \u00b1 500||7,300 \u00b1 1,400 >8,300||830 \u00b1 110 12,000 \u00b1 1,400||210 \u00b1 40 3,000 \u00b1 540||230.0||15.0 |- |4-chloro||neopentyl||H||120 \u00b1 40 600 \u00b1 40||60 \u00b1 2 670 \u00b1 260||3,900 \u00b1 500 3,500 \u00b1 1,000||>8,300 1,800 \u00b1 600||1,400 \u00b1 400 >5,500||520 \u00b1 110 730 \u00b1 250||12.0||8.7 |- |4-chloro||cyclopentylmethyl||H||9.4 \u00b1 1.5 310 \u00b1 80||21 \u00b1 1 180 \u00b1 20||2,900 \u00b1 80 3,200 \u00b1 700||2,100 \u00b1 900 5,600 \u00b1 1,400||1,700 \u00b1 600 2,600 \u00b1 800||310 \u00b1 40 730 \u00b1 230||180.0||15.0 |- |4-chloro||cyclohexylmethyl||H||130 \u00b1 40 260 \u00b1 30||230 \u00b1 70 410 \u00b1 60||900 \u00b1 400 3,700 \u00b1 500||1,000 \u00b1 200 6,400 \u00b1 1,300||4,200 \u00b1 200 4,300 \u00b1 200||940 \u00b1 140 1,700 \u00b1 600||32.0||4.1 |- |4-chloro||benzyl||H||440 \u00b1 110 550 \u00b1 60||370 \u00b1 90 390 \u00b1 60||1,100 \u00b1 200 4,300 \u00b1 800||1,100 \u00b1 200 4,700 \u00b1 500||2,900 \u00b1 800 4,000 \u00b1 800||2,900 \u00b1 600 >8,800||6.6||7.8 |- |4-chloro||phenethyl||H||24 \u00b1 9 700 \u00b1 90||160 \u00b1 20 420 \u00b1 140||640 \u00b1 60 1,800 \u00b1 70||650 \u00b1 210 210 \u00b1 900d||1,800 \u00b1 600 2,400 \u00b1 700||680 \u00b1 240 610 \u00b1 150||75.0||4.3 |- |4-chloro||phenpropyl||H||440 \u00b1 150 2,900 \u00b1 900||290 \u00b1 90 1,400 \u00b1 400||700 \u00b1 200 1,500 \u00b1 200||1,600 \u00b1 300 1,200 \u00b1 400||490 \u00b1 100 1,500 \u00b1 200||600 \u00b1 140 1,700 \u00b1 200||1.1||2.1 |- |4-chloro||3-pentyl||H||400 \u00b1 80 >5,700||240 \u00b1 60 1,200 \u00b1 90||3,900 \u00b1 300 4,800 \u00b1 1,100||>9,400 >9,600||970 \u00b1 290 4,300 \u00b1 200||330 \u00b1 80 3,800 \u00b1 30||2.4||1.4 |- |4-chloro||cyclopentyl||H||36 \u00b1 10 690 \u00b1 140||27 \u00b1 8.3 240 \u00b1 30||5,700 \u00b1 1,100 4,600 \u00b1 700||4,600 \u00b1 800 4,200 \u00b1 900||380 \u00b1 120 3,300 \u00b1 800||44 \u00b1 18 1,000 \u00b1 300||11.0||1.6 |- |3-chloro||isobutyl||H||3.7 \u00b1 1.1 140 \u00b1 30||2.8 \u00b1 0.4 88 \u00b1 12||3,200 \u00b1 400 3,200 \u00b1 400||2,100 \u00b1 100 870 \u00b1 230||23 \u00b1 6 340 \u00b1 50||14 \u00b1 1 73 \u00b1 5||6.2||5.0 |- |3,4-dichloro||COOCH3||H||1.4 \u00b1 0.1 90 \u00b1 14||23 \u00b1 3 800 \u00b1 110||1,600 \u00b1 150 2,500 \u00b1 420||540 \u00b1 110 1,100 \u00b1 90||14 \u00b1 6 4,200 \u00b1 1,900||10 \u00b1 1 190 \u00b1 50||10.0||0.43 |- |3,4-dichloro||propyl||H||0.97 \u00b1 0.31 43 \u00b1 9||4.5 \u00b1 0.4 88 \u00b1 32||1,800 \u00b1 500 450 \u00b1 80||560 \u00b1 120 180 \u00b1 60||3.9 \u00b1 1.4 30 \u00b1 8||8.1 \u00b1 3.8 47 \u00b1 22||4.0||1.8 |- |3,4-dichloro||butyl||H||2.3 \u00b1 0.2 29 \u00b1 5||5.7 \u00b1 0.5 67 \u00b1 13||1,300 \u00b1 300 1,100 \u00b1 200||1,400 \u00b1 300 550 \u00b1 80||12 \u00b1 3 31 \u00b1 11||27 \u00b1 10 63 \u00b1 27||5.2||4.7 |- |3,4-dichloro||isobutyl||H||1.0 \u00b1 0.5 31 \u00b1 11||5.5 \u00b1 1.3 13 \u00b1 3||1,600 \u00b1 100 450 \u00b1 40||1,100 \u00b1 300 290 \u00b1 60||25 \u00b1 9 120 \u00b1 30||9.0 \u00b1 1.2 19 \u00b1 3||25.0||1.6 |- |3,4-dichloro||isobutyl||CH3||6.6 \u00b1 0.9 44 \u00b1 12||13 \u00b1 4 45 \u00b1 4||1,300 \u00b1 200 1,500 \u00b1 300||1,400 \u00b1 500 2,400 \u00b1 700||190 \u00b1 60 660 \u00b1 130||28 \u00b1 3 100 \u00b1 19||29.0||2.2 |- |4-methoxy||isobutyl||H||52 \u00b1 16 770 \u00b1 220||25 \u00b1 9 400 \u00b1 120||2,800 \u00b1 600 950 \u00b1 190||3,500 \u00b1 500 1,200 \u00b1 300||3,100 \u00b1 200 16,000 \u00b1 2,000||410 \u00b1 90 1,600 \u00b1 400||60.0||16.0 |- |3-methoxy||isobutyl||H||22 \u00b1 5 950 \u00b1 190||35 \u00b1 12 140 \u00b1 20||4,200 \u00b1 400 3,800 \u00b1 600||2,700 \u00b1 800 2,600 \u00b1 300||3,800 \u00b1 500 12,000 \u00b1 2,300||330 \u00b1 40 1,400 \u00b1 90||170.0||9.4 |- |4-isopropyl||isobutyl||H||3,300 \u00b1 600 >6,500||4,000 \u00b1 400 >9,100||3,300 \u00b1 600 1,700 \u00b1 500||4,700 \u00b1 700 1,700 \u00b1 100||2,500 \u00b1 600 3,200 \u00b1 600||7,100 \u00b1 1,800 >8,700||0.76||1.8 |- |H||COCH3||H||370 \u00b1 70||190 \u00b1 50||7,800 \u00b1 1,200||>9,700||2,700 \u00b1 400||220 \u00b1 30||7.3||1.2 |} *\u0251H = Equivalent overlay of structure sharing functional group *bCO2CH3 (i.e. COOCH3) = Equivalent overlay of structure sharing functional group *cCH3 = Equivalent overlay of structure sharing functional group *dpossible typographical error in original source; e.g. 2,100 \u00b1 900 or 900 \u00b1 210 ==Restricted rotational analogs of methylphenidate (quinolizidines)== Two of the compounds tested, the weakest two @ DAT & second to the final two on the table below, were designed to elucidate the necessity of both constrained rings in the efficacy of the below series of compounds at binding by removing one or the other of the two rings in their entirety. The first of the two retain the original piperidine ring had with methylphenidate but has the constrained B ring that is common to the restricted rotational analogues thereof removed. The one below lacks the piperdine ring native to methylphenidate but keeps the ring that hindered the flexibility of the original MPH conformation. Though their potency at binding is weak in comparison to the series, with the potency shared being approximately equal between the two; the latter compound (the one more nearly resembling the substrate class of dopaminergic releasing agents similar to phenmetrazine) is 8.3-fold more potent @ DA uptake. {| class=\"wikitable sortable\" |+Binding assaysg of rigid methylphenidate analogues ! Compound\u0251 ! R & X substitution(s) ! Ki (nM) @ DAT with [33]WIN 35,065-2 ! nH @ DAT with [33]WIN 35,065-2 ! Ki (nM) or % inhibition @ NET with [33]Nisoxetine ! nH @ NET with [33]Nisoxetine ! Ki (nM) or % inhibition @ 5-HTT with [33]Citalopram ! nH @ 5-HTT with [33]Citalopram ! [33]DA uptake IC50 (nM) ! Selectivity [33]Citalopram / [33]WIN 35,065-2 ! Selectivity [33]Nisoxetine / [33]WIN 35,065-2 ! Selectivity [33]Citalopram / [33]Nisoxetine |- | Cocaine||\u2014||156 \u00b1 11||1.03 \u00b1 0.01||1,930 \u00b1 360||0.82 \u00b1 0.05||306 \u00b1 13||1.12 \u00b1 0.15||404 \u00b1 26||2.0||12||0.16 |- | Methylphenidate||\u2014||74.6 \u00b1 7.4||0.96 \u00b1 0.08||270 \u00b1 23||0.76 \u00b1 0.06||14 \u00b1 8%f||\u2014||230 \u00b1 16||>130||3.6||>47 |- | 3\u2032,4\u2032-dichloro-MPH ||\u2014||4.76 \u00b1 0.62||2.07 \u00b1 0.05||NDh||\u2014||667 \u00b1 83||1.07 \u00b1 0.04||7.00 \u00b1 140||140||\u2014||\u2014 |- |rowspan=2|70px |- |\u2014||6,610 \u00b1 440||0.91 \u00b1 0.01||11%b||\u2014||3,550 \u00b1 70||1.79 \u00b1 0.55||8,490 \u00b1 1,800||0.54||>0.76||<0.7 |- |rowspan=4|80px |- |H||76.2 \u00b1 3.4||1.05 \u00b1 0.05||138 \u00b1 9.0||1.12 \u00b1 0.20||5,140 \u00b1 670||1.29 \u00b1 0.40||244 \u00b1 2.5||67||1.8||37 |- |3\u2032,4\u2032-diCl||3.39 \u00b1 0.77||1.25 \u00b1 0.29||28.4 \u00b1 2.5||1.56 \u00b1 0.80||121 \u00b1 17||1.16 \u00b1 0.31||11.0 \u00b1 0.00||36||8.4||4.3 |- |2\u2032-Cl ||480 \u00b1 46||1.00 \u00b1 0.09||2,750; 58%b||0.96||1,840 \u00b1 70||1.18 \u00b1 0.06||1,260 \u00b1 290||3.8||5.7||0.67 |- |rowspan=2|80px |- |\u2014||34.6 \u00b1 7.6||0.95 \u00b1 0.18||160 \u00b1 18||1.28 \u00b1 0.12||102 \u00b1 8.2||1.01 \u00b1 0.02||87.6 \u00b1 0.35||3.0||4.6||0.64 |- |rowspan=3|80px |- |CH2OH||2,100 \u00b1 697||0.87 \u00b1 0.09||NDh||\u2014||16.2 \u00b1 0.05%f||\u2014||10,400 \u00b1 530||>4.8||\u2014||\u2014 |- |CH3||7,610 \u00b1 800||1.02 \u00b1 0.03||8.3%b||\u2014||11 \u00b1 5%f||\u2014||7,960 \u00b1 290||>1.3||\u226b0.66||\u2014 |- |rowspan=4|80px |- |d R=OCH3, X=H||570 \u00b1 49||0.94 \u00b1 0.10||2,040; 64 \u00b1 1.7%f||0.73||14 \u00b1 3%f||\u2014||1,850 \u00b1 160||>18||3.6||>4.9 |- |R=OH, X=H||6,250 \u00b1 280||0.86 \u00b1 0.03||23.7 \u00b1 4.1%b||\u2014||1 \u00b1 1%f||\u2014||10,700 \u00b1 750||\u226b1.6||>0.80||\u2014 |- |R=OH, X=3\u2032,4\u2032-diCl||35.7 \u00b1 3.2||1.00 \u00b1 0.09||367 \u00b1 42||1.74 \u00b1 0.87||2,050 \u00b1 110||1.15 \u00b1 0.12||NDh||57||10||5.6 |- |rowspan=3|80px |- |H||908 \u00b1 160||0.88 \u00b1 0.05||4030; 52%b||1.04||5 \u00b1 1%f||\u2014||12,400 \u00b1 1,500||\u226b11||4.4||\u226b2.5 |- |3\u2032,4\u2032-diCl||14.0 \u00b1 1.2||1.27 \u00b1 0.20||280 \u00b1 76||0.68 \u00b1 0.09||54 \u00b1 2%f||\u2014||NDh||~710||20||~36 |- |rowspan=4|80px |- |R=OH, X=H||108 \u00b1 7.0||0.89 \u00b1 0.10||351 \u00b1 85||0.94 \u00b1 0.27||12 \u00b1 2%f||\u2014||680 \u00b1 52||>93||3.3||>28 |- |R=OH, X=3\u2032,4\u2032-diCl||2.46 \u00b1 0.52||1.39 \u00b1 0.20||27.9 \u00b1 3.5||0.70 \u00b1 0.01||168||1.02||NDh||68||11||6.0 |- |R=OCH3, X=H ||10.8 \u00b1 0.8||0.97 \u00b1 0.07||63.7 \u00b1 2.8||0.84 \u00b1 0.04||2,070; 73 \u00b1 5%f||0.90||61.0 \u00b1 9.3||190||5.9||32 |- |rowspan=3|80px |- |R1=CH3, R2=H||178 \u00b1 28||1.23 \u00b1 0.09||694 \u00b1 65||0.88 \u00b1 0.13||427||1.39||368||2.4||3.9||0.62 |- |R1=H, R2=CH3||119 \u00b1 20||1.17 \u00b1 0.12||76.0 \u00b1 12||0.88 \u00b1 0.06||243||1.17||248||2.0||0.64||3.2 |- |rowspan=2|90px |- |\u2014||175 \u00b1 8.0||1.00 \u00b1 0.04||1,520 \u00b1 120||0.97 \u00b1 0.06||19 \u00b1 4%f||\u2014||NDh||>57||8.69||>6.6 |- |rowspan=3|80px |- |R=CH2CH3, X=H ||27.6 \u00b1 1.7||1.29 \u00b1 0.05||441 \u00b1 49||1.16 \u00b1 0.19||2,390; 80%f||1.12||NDh||87||15||5.8 |- |R=CH2CH3, X=3\u2032,4\u2032-diCl||3.44 \u00b1 0.02||1.90 \u00b1 0.05||102 \u00b1 19||1.27 \u00b1 0.10||286 \u00b1 47||1.30 \u00b1 0.10||NDh||83||30||2.8 |- |rowspan=3|80px |- |R=CH2CH3, X=H||5.51 \u00b1 0.93||1.15 \u00b1 0.03||60.8 \u00b1 9.6||0.75 \u00b1 0.07||3,550; 86%f||0.95||NDh||640||11||58 |- |R=CH2CH3, X=3\u2032,4\u2032-diCl||4.12 \u00b1 0.95||1.57 \u00b1 0.00||98.8 \u00b1 8.7||1.07 \u00b1 0.07||199 \u00b1 17||1.24 \u00b1 0.00||NDh||48||24||2.0 |- |rowspan=2|80px |- |\u2014||6,360 \u00b1 1,300||1.00 \u00b1 0.04||36 \u00b1 10%c||\u2014||22 \u00b1 7%f||\u2014||8,800 \u00b1 870||>1.6||\u2014||\u2014 |- |rowspan=2|60px |- |i \u2014||4,560 \u00b1 1,100||1.10 \u00b1 0.09||534 \u00b1 210c||0.96 \u00b1 0.08||53 \u00b1 6%f||\u2014||1,060 \u00b1 115||~2.2||0.12||~19 |- |rowspan=6|100px |- |R1=CH2OH, R2=H, X=H||406 \u00b1 4||1.07 \u00b1 0.08||NDh||\u2014||31.0 \u00b1 1.5%f||\u2014||1,520 \u00b1 15||>25||\u2014||\u2014 |- |R1=CH2OCH3, R2=H, X=H||89.9 \u00b1 9.4||0.97 \u00b1 0.04||NDh||\u2014||47.8 \u00b1 0.7%f||\u2014||281 \u00b1 19||~110||\u2014||\u2014 |- |R1=CH2OH, R2=H, X=3\u2032,4\u2032-diCl||3.91 \u00b1 0.49||1.21 \u00b1 0.06||NDh||\u2014||276; 94.6%f||0.89||22.5 \u00b1 1.4||71||\u2014||\u2014 |- |R1=H, R2=CO2CH3, X=3\u2032,4\u2032-diCl||363 \u00b1 20||1.17 \u00b1 0.41||NDh||\u2014||2,570 \u00b1 580||1.00 \u00b1 00.1||317 \u00b1 46||7.1||\u2014||\u2014 |- |R1=CO2CH3, R2=H, X=2\u2032-Cl||1,740 \u00b1 200||0.98 \u00b1 0.02||NDh||\u2014||22.2 \u00b1 2.5%f||\u2014||2,660 \u00b1 140||>5.7||\u2014||\u2014 |} *\u0251Compounds tested as hydroclhoride (HCl) salts, unless otherwise noted. *b% inhibition caused by 5\u03bcM *c% inhibition caused by 10\u03bcM, as assayed by SRI *dTested as free base *eAssayed by SRI (appropriate correction factor applied.) *f% inhibition of 10\u03bcM compound. *gValues expressed as x \u00b1 SEM of 2\u20145 replicate tests. (If no SEM shown, value is for an n of 1.) *hNot determined *icf. phenmetrazine & derivatives ==Various MPH congener affinity values inclusive of norepinephrine & serotonin== Values for dl-threo-methylphenidate derivatives are the mean (s.d.) of 3\u20146 determinations, or are the mean of duplicate determinations. Values of other compounds are the mean\u2014s.d. for 3\u20144 determinations where indicated, or are results of single experiments which agree with the literature. All binding experiments were done in triplicate. {| class=\"wikitable sortable\" |+Binding and uptake IC50 (nM) values for MAT. ! Compound ! DA ! DA Uptake ! NE ! 5HT |- | Methylphenidate ||84 \u00b1 33||153 \u00b1 92||514 \u00b1 74||>50,000 |- | o-Bromomethylphenidate ||880 \u00b1 316||\u2014||20,000||\u2014 |- | m-Bromomethylphenidate ||4 \u00b1 1||18 \u00b1 11||20 \u00b1 6||3,800 |- | p-Bromomethylphenidate ||21 \u00b1 3||45 \u00b1 19||31 \u00b1 7||2,600 |- | p-Hydroxymethylphenidate ||125||263 \u00b1 74||270 \u00b1 69||17,000 |- | p-Methyloxymethylphenidate ||42 \u00b1 24||490 \u00b1 270||410||11,000 |- | p-Nitromethylphenidate ||180||\u2014||360||5,900 |- | p-Iodomethylphenidate ||26 \u00b1 14||\u2014||32||1,800\u0251 |- | m-Iodo-p-hydroxymethylphenidate ||42 \u00b1 21||195 \u00b1 197||370 \u00b1 64||5,900 |- | N-Methylmethylphenidate ||1,400||\u2014||2,800||40,000 |- | d-threo-Methylphenidate ||33||\u2014||244 \u00b1 142||>50,000 |- | l-threo- Methylphenidate ||540||\u2014||5,100||>50,000 |- | dl-erythro-o- Bromomethylphenidate ||10,000||\u2014||50,000||\u2014 |- | Cocaine ||120||313 \u00b1 160||2,100||190 |- | WIN 35,428 ||13||\u2014||530||72 |- | Nomifensine ||29 \u00b1 16||\u2014||15 \u00b1 2||1,300\u0251 |- | Mazindol ||9 \u00b1 5||\u2014||3 \u00b1 2||92 |- | Desipramine ||1,400||\u2014||3.5||200 |- | Fluoxetine ||3,300||\u2014||3,400||2.4 |} *\u0251Denotes that preparation of membrane and results extrapolated therefrom originated from frozen tissue, which is known to change results when interpreting against fresh tissue experiments. p-hydroxymethylphenidate displays low brain penetrability, ascribed to its phenolic hydroxyl group undergoing ionization at physiological pH. ===Test environment conditioning & control studies=== {| class=\"wikitable sortable\" |+Temperature effect with Hill slope measurements on MPD binding IC50 (nM) values for MAT. ! Compound ! 0\u00b0 (zero degrees) ! 0\u00b0 (zero degrees) Hill slope\u0251 ! 22\u00b0 (twenty-two degrees) ! 22\u00b0 (twenty-two degrees) Hill slope\u0251 ! 36\u00b0 (thirty-six degrees) ! 36\u00b0 (thirty-six degrees) Hill slope\u0251 |- |Methylphenidate (MPH, MPD)||51 \u00b1 24||0.99 \u00b1 0.11||72 \u00b1 29||0.90 \u00b1 0.10||265 \u00b1 175||0.70 \u00b1 0.02 |- |o-bromo-methylphenidate||1150 \u00b1 83||0.97 \u00b1 0.08||880 \u00b1 316||0.79 \u00b1 0.14||954 \u00b1 190||0.88 \u00b1 0.08 |} *\u0251The 'Hill' \"slope\" is a parameter for a biochemical equation named for Archibald Hill; 'degrees' in all cases refer to temperature, measurement of heat & cold, and not to angles. Thus \"Hill slope\" terminology herein has naught to do with effect of g-force or deviations of a level plane in the context of these values. == See also == \u03b2-CFT. cf. cocaine, and the phenyltropane class of drugs, including all subsets of related derivatives for either as pertaining in similarity to methylphenidate analogs. *List of modafinil analogues *List of cocaine analogues *Substituted cathinone x200px 3C-PEP (which in turn is structurally related to the GBR stimulant compounds.) == References == == Notes == == Further reading == * * * * * * * * * Category:Dopamine reuptake inhibitors Category:Norepinephrine-dopamine reuptake inhibitors Category:Carboxylate esters Category:Methyl esters Category:Methylphenidate Category:Piperidines Category:Sigma agonists Category:Sympathomimetic amines Category:Designer drugs Category:Chemical classes of psychoactive drugs ",
    "title": "List of methylphenidate analogues"
}